Stockscreener 앱 받기
65.56
1.58%
-1.05
시간 외 거래:
66.13
0.57
+0.87%
전일 마감가:
$66.61
열려 있는:
$66.75
하루 거래량:
849.00K
Relative Volume:
0.85
시가총액:
$2.22B
수익:
$55.23M
순이익/손실:
$-164.08M
주가수익비율:
-9.5763
EPS:
-6.8461
순현금흐름:
$-208.68M
1주 성능:
-2.99%
1개월 성능:
-28.49%
6개월 성능:
-0.20%
1년 성능:
+9,923%
1일 변동 폭
$65.27
$67.53
1주일 범위
$65.27
$69.85
52주 변동 폭
$0.6319
$109.00
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
65.56 | 2.25B | 55.23M | -164.08M | -208.68M | -6.8461 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 개시 | Wedbush | Neutral |
| 2026-03-17 | 개시 | TD Cowen | Buy |
| 2026-02-10 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | 개시 | Citigroup | Buy |
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Interim CFO at Nektar Therapeutics (NKTR) files initial Form 3 ownership report - Stock Titan
Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data (NKTR) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - AOL.com
A Look At Nektar Therapeutics (NKTR) Valuation After Prosight’s US$10 Million Purchase Ahead Of Phase 3 Trial - simplywall.st
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - The Motley Fool
Prosight Management Increases Stake in Nektar Therapeutics - Intellectia AI
Nektar TherapeuticsCommon Stock (NQ: NKTR - The Chronicle-Journal
Nektar Therapeutics R&D chief sells $13,036 in shares - Investing.com UK
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics R&D chief sells $13,036 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares - Investing.com
Nektar Therapeutics (NKTR) R&D chief sells shares to cover RSU tax - Stock Titan
Nektar Therapeutics (NKTR) CEO logs small 444-share tax-related stock sale - Stock Titan
Is Nektar Therapeutics’ (NKTR) New CFO Hire and Equity Program Reframing Its Capital-Market Strategy? - simplywall.st
Nektar Q1 earnings & revenues lag estimates, pipeline in focus - MSN
NKTR Stock Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Names Linda Rubinstein CFO As Funding And Dilution Questions Loom - simplywall.st
[144] NEKTAR THERAPEUTICS SEC Filing - Stock Titan
Why Nektar Therapeutics Stock Rocked it Today - MSN
Nektar Therapeutics stock (US6354171056): FDA update and pipeline focus - AD HOC NEWS
Patient Square Capital LP Acquires 210,000 Shares of Nektar Therapeutics in Q1 2026News and Statistics - IndexBox
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares - AOL.com
BVF Group (NKTR) reports up to 2.85M shares—9.8% aggregate holding - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - 富途牛牛
Nektar Therapeutics stock (US6354171056): $400M capital raise fuels Phase 3 autoimmune pipeline - AD HOC NEWS
NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery - simplywall.st
Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum - Yahoo Finance
Nektar Therapeutics Raises $374 Million After Alopecia Data Release; AnaptysBio’s First Tracks Bio Debuts on NASDAQ - geneonline.com
Why Nektar Therapeutics Shares Are Sliding Now - TipRanks
Nektar Therapeutics adds to its 129% two-month run with alopecia news - MSN
H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $185 - 富途牛牛
Earnings Update: Here's Why Analysts Just Lifted Their Nektar Therapeutics (NASDAQ:NKTR) Price Target To US$153 - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Pretty Bullish On The Stock After Recent Results - 富途牛牛
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $134 to $185 - Moomoo
Nektar posts 52-week data from mid-stage trial for hair loss therapy - msn.com
Nektar Therapeutics Enters Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright – 8-K Filing Details 27 - Minichart
Nektar Therapeutics Charts Aggressive Path With REZPEG - TipRanks
Nektar Therapeutics Names Rubinstein New Interim CFO - Moomoo
Nektar Therapeutics Establishes New Equity Distribution Agreement - TipRanks
Nektar Therapeutics announces $150 million equity distribution agreement and CFO transition - Investing.com Australia
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):